Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$68.98 USD

68.98
1,747,081

+1.03 (1.52%)

Updated Aug 13, 2025 04:00 PM ET

After-Market: $69.00 +0.02 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Hologic's (HOLX) Q2 Earnings Beat Estimates, 2023 View Up

by Zacks Equity Research

The year-over-year growth in Breast Health and GYN Surgical Businesses contributed to Hologic's (HOLX) Q2 revenues.

Zacks Equity Research

Hologic (HOLX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Hologic (HOLX) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Hologic (HOLX) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Hologic (HOLX) delivered earnings and revenue surprises of 20.45% and 6.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Retain Neogen (NEOG) Stock for Now

by Zacks Equity Research

Investors are optimistic about Neogen (NEOG) owing to strong performance across its Animal Safety and Food Safety segments.

Zacks Equity Research

Integra LifeSciences (IART) Q1 Earnings Meet Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of 0% and 2%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Invest in Edwards Lifesciences (EW) Now

by Zacks Equity Research

Investors are optimistic about Edwards Lifesciences (EW) on the increased adoption of its premium RESILIA technologies.

Zacks Equity Research

Hologic (HOLX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Hologic (HOLX) closed at $85.63 in the latest trading session, marking a +1.87% move from the prior day.

Zacks Equity Research

GYN Surgical Sales to Aid Hologic (HOLX) in Q2 Earnings

by Zacks Equity Research

Strong performance led by MyoSure and NovaSure is expected to have driven Hologic' s (HOLX) Q2 performance.

Zacks Equity Research

Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Robust performance from MyoSure and NovaSure along with increasing contributions from the company's laparoscopic portfolio are expected to have contributed to the Hologic's (HOLX) Q2 reveneus.

Zacks Equity Research

Here's Why You Should Buy Boston Scientific (BSX) Stock

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) owing to impressive growth in MedSurg market share.

Zacks Equity Research

Insulet's (PODD) New Omnipod, Strategic Moves Drive Growth

by Zacks Equity Research

Insulet (PODD) has been progressing well with respect to its four-pillar strategy, where the first two pillars include expanding access and awareness and delivering consumer-focused innovation.

Zacks Equity Research

Hologic (HOLX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Hologic (HOLX) closed the most recent trading day at $83.64, moving -0.59% from the previous trading session.

Zacks Equity Research

QuidelOrtho (QDEL) Reports Solid Preliminary Q1 Revenues

by Zacks Equity Research

QuidelOrtho's (QDEL) revenue growth in the first quarter is likely to have been boosted by continued strength in its non-respiratory product sales.

Zacks Equity Research

3 Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.

Zacks Equity Research

Here's Why You Should Invest in Henry Schein (HSIC) Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC), led by the strong potential in the company's dental technology joint venture, Henry Schein One.

Zacks Equity Research

Is Hologic (HOLX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Hologic (HOLX) and Ligand Pharmaceuticals (LGND) have performed compared to their sector so far this year.

Zacks Equity Research

Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Bio-Rad (BIO) Rises 6.5% Since Q4 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Bio-Rad's (BIO) strong global presence and stable solvency position.

Zacks Equity Research

Merit Medical (MMSI) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Merit Medical's (MMSI) strong product portfolio.

Zacks Equity Research

Globus' (GMED) NUVA Buyout Seems Strategic, Cost Woe Stays

by Zacks Equity Research

Globus Medical (GMED) and NuVasive (NUVA) are currently planning to combine in an all-stock transaction to create a global musculoskeletal company.

Zacks Equity Research

Amedisys (AMED) New Buyouts Aid Growth, CMS Ruling Unfavorable

by Zacks Equity Research

For Amedisys (AMED), dealing with the continuous shortage of clinical labo, in nursing in particular, has been challenging.

Zacks Equity Research

Myriad Genetics' (MYGN) New Pact to Boost Precision Medicine

by Zacks Equity Research

Myriad Genetics' (MYGN) latest program will increase access to affordable genetic testing. It will also aid in identifying and elevating high-risk patient care.

Zacks Equity Research

Masimo (MASI) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Masimo's (MASI) slew of product launches.

Zacks Equity Research

BD's (BDX) New Launch to Result in Optimal IV Placement

by Zacks Equity Research

BD's (BDX) latest launch is expected to advance its vision of a One-Stick Hospital Stay by improving the first-stick success in IV placements.

Zacks Equity Research

Shockwave Medical (SWAV) Moves 10.6% Higher: Will This Strength Last?

by Zacks Equity Research

Shockwave Medical (SWAV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.